Literature DB >> 17716682

An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug.

James S Bourdage1, Carolyn A Cook, Daphne L Farrington, Jana S Chain, Robert J Konrad.   

Abstract

Monoclonal antibody therapeutics typically have relatively long half-lives and can be dosed at high levels. Although formation of anti-drug antibodies (ADA) is relatively rare, detection of these antibodies can be very difficult in the presence of high circulating levels of drug. Typically these ADA are detected by bridging ELISAs which can be very sensitive to even low levels of drug. We describe an ELISA method based on affinity capture of ADA on solid-phase drug followed by removal of excess free drug, release and transfer of bound ADA and subsequent detection using biotinylated drug. The assay is both sensitive and highly tolerant to free drug with detection of 500 ng/ml of ADA readily achieved in the presence of 500 mug/ml of drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716682     DOI: 10.1016/j.jim.2007.07.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  25 in total

1.  Anti-drug Antibody Assay Validation: Improved Reporting of the Assay Selectivity via Simpler Positive Control Recovery Data Analysis.

Authors:  Boris Gorovits; Marcela Araya Roldan; Daniel Baltrukonis; Chun-Hua Cai; Jean Donley; Darshana Jani; John Kamerud; Frederick McCush; Jeffrey S Thomas; Ying Wang
Journal:  AAPS J       Date:  2019-06-18       Impact factor: 4.009

2.  Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase.

Authors:  Yuhong Xiang; John Kamerud; Jean Donley; Katrina Olson; Teresa Caiazzo; Dave Yeung; Chuenlei Parng; Boris Gorovits
Journal:  AAPS J       Date:  2018-11-06       Impact factor: 4.009

Review 3.  Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.

Authors:  Marian Kelley; Ago B Ahene; Boris Gorovits; John Kamerud; Lindsay E King; Thomas McIntosh; Jihong Yang
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

Review 4.  A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.

Authors:  J M Sailstad; L Amaravadi; A Clements-Egan; B Gorovits; H A Myler; R C Pillutla; S Pursuhothama; M Putman; M K Rose; K Sonehara; L Tang; J T Wustner
Journal:  AAPS J       Date:  2014-03-29       Impact factor: 4.009

Review 5.  Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.

Authors:  Manca Ogrič; Matic Terčelj; Sonja Praprotnik; Matija Tomšič; Borut Božič; Snezna Sodin-Semrl; Saša Čučnik
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

6.  Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab.

Authors:  Sumin Bian; Marc Ferrante; Ann Gils
Journal:  AAPS J       Date:  2016-11-21       Impact factor: 4.009

7.  Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.

Authors:  Francesca Civoli; Aparna Kasinath; Xiao-Yan Cai; Meenu Wadhwa; Andrew Exley; Philip Oldfield; Safa Alvandkouhi; Gregor Schaffar; John Chappell; Ronald Bowsher; Viswanath Devanarayan; Joseph Marini; Shannon Rebarchak; Michael Anderson; Vera Koppenburg; Todd Lester
Journal:  AAPS J       Date:  2019-12-02       Impact factor: 4.009

8.  Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.

Authors:  Zhandong Don Zhong; Adrienne Clements-Egan; Boris Gorovits; Mauricio Maia; Giane Sumner; Valerie Theobald; Yuling Wu; Manoj Rajadhyaksha
Journal:  AAPS J       Date:  2017-10-23       Impact factor: 4.009

9.  Practical application of acid dissociation in monitoring patients treated with adalimumab.

Authors:  Francisca Llinares-Tello; José Rosas-Gómez de Salazar; José Miguel Senabre-Gallego; Gregorio Santos-Soler; Carlos Santos-Ramírez; Esteban Salas-Heredia; Xavier Barber-Vallés; Juan Molina-García
Journal:  Rheumatol Int       Date:  2014-05-10       Impact factor: 2.631

Review 10.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.